Form 4: Amneal Pharmaceuticals Director Reports Stock Unit Activity

Director Deborah M. Autor reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock units.

Summary

• On May 5, 2025, Director Deborah M. Autor reported transactions involving Amneal Pharmaceuticals, Inc. Class A Common Stock.
• Autor acquired 40,258 shares through the vesting of restricted stock units.
• Following the transaction, Autor directly owns 93,660 shares of Class A Common Stock.
• Additionally, Autor acquired 34,819 restricted stock units on May 6, 2025, which vest on the later of the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and the day immediately following the first anniversary of the date of grant.
• These restricted stock units represent a contingent right to receive one share of the Issuer's Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock unit activity by a director. The acquisition of shares through vesting is generally a positive sign, but it's not a major event.

Positives

• The director's acquisition of shares through vesting could be seen as a positive signal, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the restricted stock units acquired on May 6, 2025, depends on the timing of Amneal Pharmaceuticals' future annual meetings.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• Shareholders are informed about the director's stock transactions, providing transparency into insider activity.

Key Dates

Keywords

Amneal Pharmaceuticals, Director, Stock Units, Class A Common Stock, Beneficial Ownership, Restricted Stock Units, Form 4, AMRX